OR WAIT null SECS
March 22, 2017
In a FDAVoice blog post, CBER Director Peter Marks discusses the new designation for cell therapies that treat life-threatening diseases.
March 17, 2017
Caladrius is selling the remaining percentage of the subsidiary in order to focus on cell therapy development.
The company announced that it would now be offering a portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing.
March 01, 2017
The UK Stem Cell Bank released validated stem-cell lines for researchers developing novel cell-based therapies for clinical trials.
January 25, 2017
Researchers from Cellectis investigate how external signals in the tumor microenvironment could control the cell-surface expression and specificity of engineered CARs.
January 10, 2017
Language surrounding regenerative medicine and the REGROW Act appeared back into the 21st Century Cures Act right before it passed. What will this mean for the controversial testing and marketing of stem-cell therapies?
December 15, 2016
Oxford Genetics received £1.61 million from Innovate UK to explore computational and synthetic biology approaches for optimized mammalian bioproduction.
December 08, 2016
At the American Society of Hematology Annual Meeting, Novartis and Kite Pharma both released results from early-phase clinical trials with CAR-T therapies.
October 24, 2016
FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.
August 02, 2016
The acquisition will add to the company's cell therapy base and potential impact in treating rare diseases.